NCT03486730: BT1718 in Patients With Advanced Solid Tumours

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MT1-MMP
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 16 Years and older (Child, Adult), Senior)
Location of Metastases: 
Additional Notes: Only triple negative patients with MT1-MMP expression will be eligible for phase 1a

Up ↑